Literature DB >> 2360818

Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

M J Rybak1, L M Albrecht, J R Berman, L H Warbasse, C K Svensson.   

Abstract

The pharmacokinetics of vancomycin were evaluated in 34 patients (10 burn patients, 14 intravenous drug abusers [IVDA], and 10 controls). Multiple serum samples were drawn following a 1-h vancomycin infusion at steady state over an 8- to 12-h dosing interval. Pharmacokinetic parameters were derived by noncompartmental analysis. There were no significant differences among the groups with respect to age, weight, serum creatinine, volume of distribution, or protein binding. Burn patients had a significantly higher creatinine clearance than did IVDA or controls. Vancomycin clearances averaged 142.8, 98.0, and 67.7 ml/min in burn patients, IVDA, and controls, respectively. The renal clearance of vancomycin was also higher in burn patients than in the other groups. IVDA tended to have a higher vancomycin clearance (31% higher) than did controls, but the difference was not statistically significant. Vancomycin clearance was much higher in burn patients requiring dosage individualization and close monitoring. A considerable amount of vancomycin was eliminated through renal tubular secretion, making dosage predictions based on creatinine clearance more difficult. Further work with IVDA will be needed to determine if they represent a group requiring aggressive vancomycin dosages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360818      PMCID: PMC171693          DOI: 10.1128/AAC.34.5.792

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Altered vancomycin dose vs. serum concentration relationship in burn patients.

Authors:  J C Garrelts; J D Peterie
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

2.  Noncompartmental determination of the steady-state volume of distribution during multiple dosing.

Authors:  I L Smith; J J Schentag
Journal:  J Pharm Sci       Date:  1984-02       Impact factor: 3.534

3.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

Review 4.  Drug kinetics in burn patients.

Authors:  R J Sawchuk; T S Rector
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

5.  Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide.

Authors:  Y Nivoche; A Contrepois; A C Cremieux; C Carbon
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

6.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs.

Authors:  C H King; R J Creger; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Vancomycin pharmacokinetics in critically ill patients.

Authors:  J J Garaud; B Regnier; F Inglebert; F Faurisson; J Bauchet; F Vachon
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

9.  Vancomycin elimination in patients with burn injury.

Authors:  D C Brater; R E Bawdon; S A Anderson; G F Purdue; J L Hunt
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

10.  Postburn serum drug binding and serum protein concentrations.

Authors:  D C Bloedow; J F Hansbrough; T Hardin; M Simons
Journal:  J Clin Pharmacol       Date:  1986-02       Impact factor: 3.126

View more
  29 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Population pharmacokinetics of arbekacin in burn patients.

Authors:  Jong Hyun Kim; Hyon-Oh Lah; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

6.  Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.

Authors:  Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich
Journal:  Can J Hosp Pharm       Date:  2010-05

Review 7.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

9.  Infective Endocarditis in Intravenous Drug Abusers.

Authors:  José M. Miró; Asuncion Moreno; Carlos A. Mestres
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

Review 10.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.